L. Nathan Tumey joined Binghamton University in 2017, following 15 years of experience in the pharmaceutical and biotechnology industry. He received his PhD in chemistry from Duke University in 2001, under the supervision of Michael Pirrung. His research emphasis was on the medicinal chemistry of LpxC inhibitors as antibacterial agents against gram negative bacteria. Following his PhD, Tumey joined Athersys, Inc. in Cleveland, Ohio, where he was responsible for hit-to-lead development for multiple medicinal chemistry programs, most notably the development of two novel series of antagonists for CRTH-2 as a potential treatment for asthma. In 2006, Tumey joined Pfizer, Inc. where he led a multidisciplinary team of scientists developing inhibitors of IRAK-4, a kinase involved in the innate immune response which is critical to signaling from Toll-like receptors. Under his leadership, the team from Pfizer was able to develop highly selective sub-nM inhibitors of the enzyme that showed promise in preclinical models of inflammation.
In 2010, Tumey embarked on a significant career transition, moving away from small-molecule medicinal chemistry and joining a newly formed team of scientists at Pfizer tasked with developing next-generation antibody-drug conjugates (ADCs) as potential treatments for cancer. In this role, Tumey has built a significant skill set and reputation in the area of ADC stability, bioanalysis and design. Most importantly, he has striven to bring the rigor of small molecule medicinal chemistry into the challenging field of targeted drug delivery. Research in Tumey's lab has led to new methods for monitoring and optimizing ADC stability, new chemical release strategies for therapeutically active payloads and better understanding of factors that drive ADC PK. This work has been widely recognized in the ADC community. For example, his work describing efforts to mitigate the rapid metabolism of a tubulysin ADC was selected as the cover article for the November 2016 issue of ACS Medicinal Chemistry Letters.
At Binghamton, Tumey's research focuses on the application of antibody-drug conjugates and related modalities for the treatment of auto-immune diseases and rare diseases. Additionally, his lab investigates bioconjugate stability, non-antibody targeting techniques and mechanism of payload-release from bioconjugates.
Tumey is the corresponding author on 14 publications and is a co-author on more than a dozen additional publications. He is a co-inventor of more than 13 patent applications and has been an invited speaker at several national and international scientific meetings. Tumey's expertise includes bioconjugation, bioanalytical chemistry, small molecule synthesis, and drug-design. Outside of laboratory, Tumey enjoys the spending time with his wife, Susan, and their two daughters. He also enjoys hiking, camping and skiing.
- BS, King University
- PhD, Duke University
- Medicinal chemistry
- Targeted drug delivery
- Antibody-drug conjugates
- Auto-immune disease / inflammation